Treatment with IFN-β is an efficient and safe way of treating MS within the escalating therapy approach, but the broad spectrum of patient responses suggests a nuanced interplay between treatment efficacy and individual genetic predisposition. The gene discussed is IFNB1; the disease is myeloid sarcoma.